Core Viewpoint - Inspire Medical Systems (INSP) is expected to report a quarterly earnings per share (EPS) of $0.06, reflecting a year-over-year increase of 120.7%, with revenues projected at $197.65 million, a 28.9% increase compared to the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not reassessed their initial estimates during this period [2]. - Revisions to earnings projections are crucial for predicting investor behavior regarding the stock, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue Projections - Analysts estimate that 'Geographic Revenue - United States' will reach $191.01 million, representing a year-over-year increase of 29.5% [5]. - The consensus estimate for 'Geographic Revenue - All other countries' is $6.68 million, indicating a year-over-year increase of 15.5% [5]. Medical Centers and Sales Territories - Analysts predict that 'New U.S. Medical Centers' will total 53, down from 62 in the previous year [5]. - The total number of 'U.S. Medical Centers' is expected to reach 1,369, up from 1,107 in the same quarter last year [6]. - 'New U.S. sales territories' are projected to remain at 13, while 'Total U.S. sales territories' are expected to increase to 323 from 274 year-over-year [6]. Stock Performance - Shares of Inspire have decreased by 4.9% over the past month, contrasting with a 1.8% increase in the Zacks S&P 500 composite [7]. - With a Zacks Rank of 2 (Buy), INSP is anticipated to outperform the overall market in the near future [7].

Inspire Medical Systems (INSP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Individual ...

MINNEAPOLIS, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2024 after the close of trading on Monday, November 4. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q3 20 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? T ...

MINNEAPOLIS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024. Inspire is scheduled to present at the Morgan Sta ...

Inspire Medical Systems (INSP) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this maker of devices for treating obstructive sleep apnea, should get reflected in its stock price. After all, empirical research shows a strong c ...

Inspire Medical Systems, Inc. (INSP) reported earnings per share of 32 cents for the second quarter of 2024 against the Zacks Consensus Estimate of a loss of 14 cents per share. In the year-ago period, the company had incurred a loss of 41 cents per share. Revenues in Detail Inspire Medical registered revenues of $195.9 million in the second quarter, up 29.8% year over year. The figure beat the Zacks Consensus Estimate by 3.7%. Segment Details Inspire Medical's operations consist of two geographic regions — ...

Financial Data and Key Metrics Changes - The company generated revenue of $195.9 million in Q2 2024, a 30% increase compared to Q2 2023 [5][17] - U.S. revenue totaled $187.8 million, also a 30% increase year-over-year [5][19] - Net income for Q2 was $9.8 million, compared to a net loss of $12 million in the prior year, resulting in net income per share of $0.32 [6][19] - The company raised its full-year revenue guidance to $788 million to $798 million, representing 26% to 28% growth over 2023 [6][20] Business Line Data and Key Metrics Changes - Revenue outside the U.S. increased by 27% to $8.1 million, with notable growth in Germany, Switzerland, the Netherlands, and Belgium [6][17] - The gross margin in Q2 was 84.8%, up from 83.9% in the prior year, driven by increased sales volumes and manufacturing efficiencies [17] Market Data and Key Metrics Changes - The company expanded its U.S. presence with 81 new implanted centers and 12 new sales territories, bringing the total to 1,316 active U.S. centers and 310 sales territories [5][6] - The proposed 2025 National Medicare outpatient payment rates indicate a 2% increase, which is favorable for the company [11] Company Strategy and Development Direction - The company is focused on operational readiness for the Inspire V neurostimulation system, with a soft launch planned for May 2024 and a full launch in 2025 [9][32] - The company aims to improve patient experience through initiatives like digital scheduling, which has increased appointment scheduling success by 60% [13] - The company is also enhancing its market access through the PREDICTOR study, which aims to simplify the process for patients with lower BMI [10][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum going forward, citing resolved prior authorization challenges and strong patient demand [23] - The company anticipates continued growth driven by the adoption of Inspire therapy and the introduction of Inspire V [63] - Management highlighted the importance of GLP-1 therapies in complementing Inspire therapy, with over 1,500 patients receiving both therapies in the past two years [41][42] Other Important Information - The company announced a $150 million share repurchase authorization, marking the first in its history [15][20] - The company is actively working with payers to improve patient access and streamline reimbursement processes [49] Q&A Session Summary Question: Insights on the recent quarter's performance and future expectations - Management clarified that the strong Q2 performance was not merely a catch-up from Q1 but a reflection of improved operational momentum and patient demand [23] Question: Profitability and cost savings - Management indicated that improved productivity and targeted investments in digital advertising contributed to profitability, with expectations for continued operating leverage [25] Question: U.S. utilization and seasonal trends - Management acknowledged historical seasonality but expressed confidence in sequential and year-over-year utilization growth moving forward [28] Question: Inspire V rollout details - The company confirmed a soft launch for Inspire V in select centers, with a full launch expected in 2025, emphasizing the importance of operational readiness [32] Question: Impact of GLP-1 therapies on patient qualification - Management noted significant evidence of patients on GLP-1 therapies benefiting from Inspire therapy, with ongoing efforts to communicate this to physicians [41][42] Question: Surgeon capacity and operational efficiencies - Management discussed initiatives to improve surgeon capacity, including the use of advanced practice providers to streamline patient care processes [45]

For the quarter ended June 2024, Inspire Medical Systems (INSP) reported revenue of $195.89 million, up 29.7% over the same period last year. EPS came in at $0.32, compared to -$0.41 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $195.9 million, representing a surprise of -0.01%. The company delivered an EPS surprise of +328.57%, with the consensus EPS estimate being -$0.14. While investors scrutinize revenue and earnings changes year-over-year and how they compare ...

Inspire Medical Systems (INSP) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 328.57%. A quarter ago, it was expected that this maker of devices for treating obstructive sleep apnea would post a loss of $0.63 per share when it actually produced a loss of $0.34, delivering a su ...